Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Mexico: Health Agency...

    Mexico: Health Agency Cofepris approves Tesamorelin Vial Drug for HIV Patients

    Written by savita thakur thakur Published On 2016-03-10T07:07:30+05:30  |  Updated On 10 March 2016 7:07 AM IST
    Canada: Theratechnologies Inc (Theratechnologies) (TSX:TH) announces that COFEPRIS, Mexico's health agency, has approved the 1mg/vial presentation of tesamorelin for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, allowing the commercialization of EGRIFTA® in this territory.

    The approval of the 1mg/vial presentation comes in the footsteps of the 2mg/vial presentation approval which was received last July from Mexico' s health agency.

    "We are very excited by this news especially since it is the result of a long process. We have reached another important milestone towards our goal to offer EGRIFTA® to patients who are looking for a product addressing their condition. Our partner can now focus on the next steps in Mexico consisting in seeking reimbursement for the product and commercializing it," said Luc Tanguay, President and CEO, Theratechnologies Inc.

    EGRIFTA® was first approved by the United States Food and Drug Administration in November 2010 and by Health Canada in March 2015.
    COFEPRISEGRIFTAHIVlipodystrophyLuc TanguayMexico's health agencyTheratechnologies IncTSX:THUnited States Food and Drug AdministrationUSFDA
    Source : Marketwired

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok